Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR8.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR7.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR9.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR6.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR3.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR2.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR4.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR1.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR5.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR25.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR17.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR26.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR45.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR39.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR29.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR10.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR41.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR32.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR22.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR44.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR30.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR15.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR42.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR23.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR28.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR18.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR12.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR27.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR19.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR11.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR38.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR43.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR40.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR36.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR37.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR34.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR31.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR13.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR24.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR14.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR33.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR16.htm
EX-32.1 - CERTIFICATION - MEDICAL INTERNATIONAL TECHNOLOGY INCf10k2012ex32i_medicalint.htm
EX-31.1 - CERTIFICATION - MEDICAL INTERNATIONAL TECHNOLOGY INCf10k2012ex31i_medicalint.htm
10-K - ANNUAL REPORT - MEDICAL INTERNATIONAL TECHNOLOGY INCf10k2012_medicalint.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR35.htm
XML - IDEA: XBRL DOCUMENT - MEDICAL INTERNATIONAL TECHNOLOGY INCR20.htm
v2.4.0.6
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Sep. 30, 2012
Summary Of Significant Accounting Policies [Abstract]  
Principles of consolidation
 
Principles of consolidation
The accompanying financial statements include the accounts and transactions of Medical International Technology, Inc. and its wholly owned subsidiaries, Medical International Technologies (MIT Canada) Inc. and 9139-2449 Quebec Inc. (dba Scanview).  Intercompany transactions and balances have been eliminated in consolidation.
Foreign Currency Translations
 
Foreign Currency Translations
The Company operates out of its offices in Montreal, Canada and maintains its books and records in Canadian Dollars. The financial statements herein have been converted into U.S. Dollars. Balance sheet accounts have been translated at exchange rates in effect at the end of the year.    Income statement accounts have been translated at average exchange rates for the year. Translation gains and losses are included as a separate component of stockholders’ equity.
Cash and Cash Equivalents
 
Cash and Cash Equivalents
For purpose of the statements of cash flows, the Company considers cash and cash equivalents to include cash on hand, amounts due to banks and any other highly liquid investments with maturities of three months or less.
Allowance for Doubtful Accounts

Allowance for Doubtful Accounts
The allowance for doubtful accounts on accounts receivable is charged to income in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired.
Inventories
 
Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. At each balance sheet date, the Company evaluates its ending inventories for excess quantities and obsolescence. This evaluation includes an analysis of sales levels by product type. Among other factors, the Company considers historical and forecasted demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining the net realizable value of the inventory. Provisions are made to reduce excess or obsolete inventories to their estimated net realizable values. Once established, write-downs are considered permanent adjustments to the cost basis of the excess or obsolete inventories.
Property and Equipment
 
Property and Equipment
The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes and on the declining balance method for income tax reporting purposes. Depreciation expense for the year ended September 30, 2012 and 2011 were $120,602 and $49,785, respectively.
Long-Lived Assets
 
Long-Lived Assets
FASB Accounting Standards Codification 360-10-40, “Property, Plant, and Equipment, Impairment of Disposal of Long-Lived Assets” (ASC 360-10-40), previously referred to as Statement of Financial Accounting Standards No. 144, “Accounting for Impairment or Disposal of Long-Lived Assets,” requires that long-lived assets, such as property and equipment and purchased intangibles subject to amortization, be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the asset is measured by comparison of its carrying amount to undiscounted future net cash flows the asset is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair market value. Estimates of expected future cash flows represent our best estimate based on currently available information and reasonable and supportable assumptions. Any impairment recognized in accordance with ASC 360-10-40 is permanent and may not be restored. As of September 30, 2012, we had not recognized any impairment of long-lived assets in connection with ASC 360-10-40 based on our reviews.
Patents
 
Patents
Patents on our technologies are being amortized over their remaining lives ranging from 7.5 years through 15 years.
Goodwill and Purchased Intangible Assets
 
Goodwill and Purchased Intangible Assets
Goodwill and identifiable intangible assets are accounted for in accordance with FASB Accounting Standards Codification 350, “Intangibles — Goodwill and Other” (ASC 350), previously referred to as Statement of Financial Accounting Standards No. 142, “Goodwill and Other Intangible Assets.” Under this standard, we assess the impairment of goodwill and identifiable intangible assets at least annually and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The first step in the assessment is the estimation of fair value. If step one indicates that impairment potentially exists, we perform the second step to measure the amount of impairment, if any. Goodwill and identifiable intangible asset impairment exists when the estimated fair value is less than its carrying value.
Revenue Recognition
 
Revenue Recognition
The Company recognizes revenue when the related product is shipped to the respective customer provided that: title and risk of loss have passed to the customer; persuasive evidence of an arrangement exists; the sales price is fixed or determinable; and collectability is deemed probable.
Stock options

Stock options
Effective October 1, 2005, we adopted the provisions of FASB Accounting Standards Codification 718, “Compensation — Stock Compensation” (ASC 718), previously referred to as Statement of Financial Accounting Standards No. 123R, “Share-Based Payment”.  We adopted ASC 718 using the modified prospective transition method. Under this transition method, compensation cost recognized includes (a) the compensation cost for all share-based awards granted prior to, but not yet vested, as of October 1, 2005, based on the grant-date fair value estimated in accordance with the original provisions of ASC 718 and (b) the compensation cost for all share-based awards granted subsequent to September 30, 2005, based on the grant-date fair value estimated in accordance with the provisions of ASC 718. Additionally, we accounted for restricted stock awards granted using the measurement and recognition provisions of ASC 718. We measure the fair value of the restricted stock awards on the grant date and recognize them in earnings over the requisite service period for each separately vesting portion of the award.

The Company determines the value of stock options utilizing the Black-Scholes option-pricing model. Compensation costs for share-based awards with pro rata vesting are allocated to periods on a straight-line basis.
Net Loss per Common Share
 
Net Loss per Common Share
Basic earnings per share (“EPS”) are computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution from the exercise or conversion of securities into common stock, including stock options and warrants. For the years ended September 30, 2012and 2011, there were no dilutive effects of such securities as the Company incurred a net loss in each period.  At September 30, 2012, the Company had outstanding warrants to purchase 3,148,332 common shares.  There were no outstanding options or warrants as of September 30, 2012.
Use of Estimates
 
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
Income Taxes
 
Income Taxes
The Company and its subsidiaries file a consolidated federal income tax return under the accrual method of accounting.  The Company accounts for income taxes under ASC 740-10-25.  Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the tax basis of assets and liabilities and their carrying values for financial reporting purposes.  When management determines that it is more than likely that a deferred tax asset will not be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities during the period.   The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that includes the enactment date.
 
Effective January 1, 2009, the Company adopted guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the financial statements and applies to all federal or state income tax positions. Each income tax position is assessed using a two step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. As of September 30, 2012 and 2011 there were no amounts that had been accrued in respect to uncertain tax positions.
 
None of the Company’s federal or state income tax returns is currently under examination by the Internal Revenue Service (“IRS”) or state authorities.  However, fiscal years 2007 and later remain subject to examination by the IRS and respective states.
Concentration of Credit Risk

Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash in banks and trade receivables.  The Company manages this risk by maintaining all deposits in high quality financial institutions and periodically performing evaluations of the relative credit standing of the financial institutions that are considered in the Company’s investment strategy. The Company grants unsecured credit to its customers during the normal course of business and performs ongoing credit evaluations of its customers to minimize any potential loss.
Fair Value of Financial Instruments
 
Fair Value of Financial Instruments
The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable and accounts payable. Management believes that the carrying values of these assets and liabilities are representative of their respective fair values based on their short-term nature.
New Accounting Pronouncements

New Accounting Pronouncements
In June 2011, the Financial Accounting Standards Board (“FASB”) issued authoritative guidance that revises the manner in which entities present comprehensive income in their financial statements. The guidance requires entities to report comprehensive income in either a single, continuous statement or two separate but consecutive statements. This guidance will become effective for fiscal years beginning after December 15, 2011; however, we have early adopted this guidance as of the end of our fiscal 2011 reporting period as permitted by the guidance. The adoption of this new guidance had no impact on our consolidated financial condition and results of operations.

In May 2011, the FASB issued authoritative guidance to amend the fair value measurement and disclosure requirements. The guidance requires the disclosure of quantitative information about unobservable inputs used a description of the valuation processes used and a qualitative discussion around the sensitivity of the measurements. The guidance will become effective for the Company at the beginning of our second quarter of fiscal 2012. We expect adoption to have no impact on our consolidated financial condition and results of operations.
Reclassifications
 
Reclassifications
Certain reclassifications have been made to the 2011 financial statements to conform to the 2012 financial statement presentation. Such reclassifications had no effect on consolidated net income as previously reported.
Investment - Equity Method and Joint Venture
 
The Company accounts for its investment in MIT China in accordance with Financial Accounting Standards Board Accounting Standards Codification 323, “Investment — Equity Method and Joint Venture” (ASC 323), previously referred to as Accounting Principles Board Opinion No. 18, “The Equity Method of Accounting for Investments in Common Stock.” Accordingly, the Company adjusts the carrying amount of its investment in MIT China to recognize its share of earnings or losses. As of September 30, 2012, the Company’s recorded investment in the MIT China was $146,343. During the year ended September 30, 2012, the Company recorded an equity loss from its investment in MIT China of $95,714.